BNP Paribas Financial Markets Raises Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

BNP Paribas Financial Markets boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 432.8% in the fourth quarter, Holdings Channel reports. The fund owned 850,823 shares of the company’s stock after purchasing an additional 691,123 shares during the quarter. BNP Paribas Financial Markets’ holdings in Apellis Pharmaceuticals were worth $27,150,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after purchasing an additional 758 shares during the period. Signaturefd LLC boosted its stake in shares of Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares during the last quarter. US Bancorp DE grew its position in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after acquiring an additional 1,327 shares during the period. Covestor Ltd increased its stake in shares of Apellis Pharmaceuticals by 1,819.2% in the 4th quarter. Covestor Ltd now owns 3,992 shares of the company’s stock worth $127,000 after purchasing an additional 3,784 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Apellis Pharmaceuticals by 89.0% in the 4th quarter. Russell Investments Group Ltd. now owns 6,107 shares of the company’s stock worth $195,000 after purchasing an additional 2,876 shares during the period. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Trading Down 0.6 %

APLS opened at $17.88 on Friday. Apellis Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $43.99. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a 50-day moving average of $21.43 and a 200 day moving average of $27.19. The firm has a market cap of $2.25 billion, a P/E ratio of -8.81 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The company had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.54) EPS. As a group, research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity

In related news, General Counsel David O. Watson sold 5,569 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares in the company, valued at approximately $3,482,123. This represents a 3.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 6,115 shares of company stock valued at $154,684. 6.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

APLS has been the subject of a number of analyst reports. Royal Bank of Canada reduced their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating for the company in a research report on Thursday. Scotiabank lowered their price target on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a report on Thursday. Wedbush reduced their price objective on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Robert W. Baird lowered their target price on shares of Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $40.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $42.11.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).